Austria-based Vela offers research activities to clinical phases and up to product commercialization to its customers.
VELA CEO Markus Fido said their customers will benefit from this alliance through more efficient project work and study design.
Protagen CEO Stefan Mullner said their customers in the pharmaceutical and biotech sector as well as CROs and CMOs will profit from this alliance through the direct access to a comprehensive service portfolio.